Selective, non-competitive NMDA receptor antagonist (IC50 = 5 μM); binds to the receptor-associated ion channel and prevents glutamate-induced Ca2+ influx. Displays neuroprotective activity in vivo. Brain-penetrant.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 304.82. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.28 mL||16.4 mL||32.81 mL|
|5 mM||0.66 mL||3.28 mL||6.56 mL|
|10 mM||0.33 mL||1.64 mL||3.28 mL|
|50 mM||0.07 mL||0.33 mL||0.66 mL|
References are publications that support the products' biological activity.
Planells-Cases et al (2002) A novel N-methyl-D-aspartate receptor open channel blocker with in vivo neuroprotectant activity. J.Pharmacol.Exp.Ther. 302 163 PMID: 12065713
If you know of a relevant reference for N20C hydrochloride, please let us know.
Keywords: N20C hydrochloride, supplier, Non-competitive, NMDA, receptor, open-channel, blockers, glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, NMDA, Receptors, NMDA, Receptors, Tocris Bioscience
1 Citation for N20C hydrochloride
Citations are publications that use Tocris products. Selected citations for N20C hydrochloride include:
Roy et al (2014) Enhancement of morphological plasticity in hippocampal neurons by a physically modified saline via phosphatidylinositol-3 kinase. J Biol Chem 9 e101883 PMID: 25007337
Do you know of a great paper that uses N20C hydrochloride from Tocris? If so please let us know.
Reviews for N20C hydrochloride
There are currently no reviews for this product. Be the first to review N20C hydrochloride and earn rewards!
Have you used N20C hydrochloride?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.